Article
Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
Nature genetics - 1 Nov 2020
Bolton Kelly L, Ptashkin Ryan N, Gao Teng, Braunstein Lior, Devlin Sean M, Kelly Daniel, Patel Minal, Berthon Antonin, Syed Aijazuddin, Yabe Mariko, Coombs Catherine C, Caltabellotta Nicole M, Walsh Mike, Offit Kenneth, Stadler Zsofia, Mandelker Diana, Schulman Jessica, Patel Akshar, Philip John, Bernard Elsa, Gundem Gunes, Ossa Juan E Arango, Levine Max, Martinez Juan S Medina, Farnoud Noushin, Glodzik Dominik, Li Sonya, Robson Mark E, Lee Choonsik, Pharoah Paul D P, Stopsack Konrad H, Spitzer Barbara, Mantha Simon, Fagin James, Boucai Laura, Gibson Christopher J, Ebert Benjamin L, Young Andrew L, Druley Todd, Takahashi Koichi, Gillis Nancy, Ball Markus, Padron Eric, Hyman David M, Baselga Jose, Norton Larry, Gardos Stuart, Klimek Virginia M, Scher Howard, Bajorin Dean, Paraiso Eder, Benayed Ryma, Arcila Maria E, Ladanyi Marc, Solit David B, Berger Michael F, Tallman Martin, Garcia-Closas Montserrat, Chatterjee Nilanjan, Diaz Luis A, Levine Ross L, Morton Lindsay M, Zehir Ahmet, Papaemmanuil Elli
Abstract excerpt
Acquired mutations are pervasive across normal tissues. However, understanding of the processes that drive transformation of certain clones to cancer is limited. Here we study this phenomenon in the context of clonal hematopoiesis (CH) and the development of therapy-related myeloid neoplasms (tMNs). We find that mutations are selected differentially based on exposures. Mutations in ASXL1 are enriched in current...
Read the complete abstract on PubMed